Eritrea- Green Light Committee Monitoring Mission 2021

WHO Regional Office for Africa

WHO Regional Office for Africa

The Green Light Committee (GLC) Initiative, together with the Working Group on MDR-TB, promotes implementation of the component two of the Stop TB Strategy that calls for the control and prevention of multidrug-resistant tuberculosis (MDR-TB) through: (i) increased access to quality-assured second-line anti-TB drugs; and (ii) prevention of development of resistance to anti-TB drugs in accordance with the Global Plan to Stop TB (2006–2015) and the Global MDR/XDR-TB Response plan (2007–2008).

It was established in 2000, and enables countries access to affordable, high-quality, second-line anti-TB drugs for the treatment of MDR-TB. Its main Objectives include ensuring effective treatment of patients with MDR-TB in accordance with guidelines published by the World Health Organization (WHO) on the programmatic management of MDR-TB; increasing access to technical assistance to facilitate rapid scale-up of MDR-TB management; increasing access to high-quality, low-cost, second-line anti-TB drugs for the treatment of MDR-TB among well-performing programmes; preventing the development of resistance to second-line anti-TB drugs by ensuring rational drug use and advising WHO on policy-related matters to effectively prevent and control MDR-TB based on the best available scientific evidence. The Initiative is coordinated by the GLC Secretariat, which is hosted and administered by WHO. The Global Drug Facility (GDF), an arm of the Stop TB Partnership, which is also hosted and administered by WHO, carries out drug procurement for GLC-approved programmes. Technical assistance to MDR-TB programmes is coordinated and delivered by WHO and its technical partners.

Eritrea conducted Green Light Committee monitoring mission during 9-18 August and 20-31 August 2021 by two TB experts namely TB Laboratory and TB Programmatic expert respectively. The main objective was to assess the TB/DR-TB program implementation, evaluate current achievements and sustainability of the program, and develop recommendations for future activities. Furthermore, annual monitoring missions are one of the conditions for implementing the Green Light Committee (GLC)-approved treatment programs for drug resistant tuberculosis (DR-TB), especially those financed from the Global Fund grants where Eritrea is funded from.

During the debriefing on 30th August 2021 that was attended by the Director of Communicable Disease Control, Dr Araia Berhane, Sr Hiwet Negusse, TB Unit Head, Dr Assefash Zehaie, WHO/ATM and focal persons of MDR-TB center, TB National Health Laboratory, National Medicine&Food Administration and Procurement Supply Management System.

Findings showed that Eritrea has achieved much that includes a new TB national strategic plan (NSP) 2021-2026 recognizes the need to ensure universal health coverage and the public health importance of DR-TB in Eritrea. The political commitment was strong as evidenced by government funding to most TB and RR/MDR-TB services, clear PMDT guidelines with identified key populations for TB, case finding strategies, treatment strategies, 2nd line anti-TB drug supply and recording and reporting. Identified key populations for active TB screening were children, persons with diabetes, nomads, miners, prisoners, elders and people living with human immunodeficiency virus (HIV) and the country adopted the universal use of Gene Xpert for all presumptive TB cases. Then recommendation, implementation plan with timeline was also delivered.

Distributed by APO Group on behalf of WHO Regional Office for Africa.

Send us your press releases to

© Press Release 2021

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.

More From Press Releases